In mouse models of JAK2 (V617F)-MPN, JAK2 inhibitors markedly reduced splenomegaly and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival of mice. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.